Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers

• Published in: Frontiers in pharmacology Vol. 8; p. 740
• Main Authors: Monteith, David, Collins, Emily C., Vandermeulen, Corinne, Van Hecken, Anne, Raddad, Eyas, Scherer, Joel C., Grayzel, David, Schuetz, Thomas J., de Hoon, Jan
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 17.10.2017
• Subjects: CGRP; dermal blood flow; headache; humanized monoclonal antibody; migraine disorders; Pharmacology; headache; humanized monoclonal antibody; CGRP; dermal blood flow; migraine disorders

Calcitonin gene-related peptide (CGRP) is pivotal in the pathophysiology of migraine headaches and represents a promising target for migraine treatment. The humanized monoclonal antibody galcanezumab (LY2951742) binds to CGRP and may be effective in migraine prophylaxis. The primary objective was to...